# Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

> **NCT02566993** · PHASE3 · COMPLETED · sponsor: **PharmaMar** · enrollment: 613 (actual)

## Conditions studied

- Small-cell Lung Cancer

## Interventions

- **DRUG:** Lurbinectedin (PM01183)
- **DRUG:** Doxorubicin (DOX)
- **DRUG:** Cyclophosphamide (CTX)
- **DRUG:** Vincristine (VCR)
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT02566993
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-30
- **Primary completion:** 2020-02-24
- **Final completion:** 2020-02-24
- **Target enrollment:** 613 (ACTUAL)
- **Last updated:** 2021-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02566993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02566993, "Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02566993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*